December 2016
-
Propeller Health announced that the FDA has granted 510(k) clearance for the company’s inhaler monitoring sensor for AstraZeneca’s Symbicort MDI. The Propeller sensor snaps on to the inhaler and connects via Bluetooth to a mobile… Read more . . .
-
Cipla said that it has received final approval for an ANDA for its generic version of Bausch’s Migranal dihydroergotamine (DHE) mesylate nasal spray for the treatment of migraine. According to Cipla, this is the company’s… Read more . . .
-
The Chinese National Medical Products Administration (NMPA) has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said. AstraZeneca’s Breztri Aerosphere budesonide/glycopyrronium/formoterol fumarate MDI was approved for the treatment of COPD by… Read more . . .
-
Covis Pharma said that it has initiated a Phase 3 of Alvesco ciclesonide MDI for the treatment of COVID-19 in US patients aged 12 and older who have not been hospitalized, with preliminary results expected… Read more . . .
-
Teva Canada said that it has imported a 4-week supply of Salamol salbutamol (albuterol) sulfate MDIs through Teva UK under an interim order by the Minister of Health in response to shortages of the inhalers in Canada caused… Read more . . .
-
Cipla has submitted an ANDA for a generic version of GSK’s Advair Diskus fluticasone propionate/salmeterol DPI in 100/50 mcg, 250/50 mcg and 500/50 dosage strengths for the treatment of asthma and COPD, the company said.… Read more . . .
-
Liquidia Technologies has announced the appointment of former Teva Pharmaceuticals Global Head of Specialty Clinical Development Tushar Shah as the company’s first Chief Medical Officer. Prior to his most recent position, Shah had served as Senior… Read more . . .
-
The organizing committee for DDL 2020, which was scheduled for December 9-11 in Edinburgh, UK, has announced the cancellation of the meeting, saying, “In addition to showcasing great new science, a major part of the… Read more . . .
-
VistaGen Therapeutics has announced that it is proposing a Phase 2a study of its PH94B aloradine nasal spray for the treatment of patients with adjustment disorder with anxiety caused by the COVID-19 pandemic, subject to approval… Read more . . .
-
Digital RDD 2020 opened on April 26 at 3 p.m. Pacific Standard Time — exactly when the meeting would have opened had it been held in California. After being forced to cancel the California meeting… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland